# C_2014440EN.01000301.xml

| 9.12.2014 | EN | Official Journal of the European Union | C 440/3 |
| --- | --- | --- | --- |

9.12.2014

EN

Official Journal of the European Union

C 440/3

---

Prior notification of a concentration

(Case M.7379 — Mylan/Abbott EPD-DM)

(Text with EEA relevance)

(2014/C 440/03)

| 1. | On 28 November 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Mylan (Mylan, US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Abbott EPD-DM (Abbott EPD-DM, Switzerland) by way of purchase of assets. |
| --- | --- |

1.

On 28 November 2014, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Mylan (Mylan, US) acquires within the meaning of Article 3(1)(b) of the Merger Regulation control of the whole of the undertaking Abbott EPD-DM (Abbott EPD-DM, Switzerland) by way of purchase of assets.

1

| 2. | The business activities of the undertakings concerned are:
  —   Mylan: a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals,
  —   Abbott EPD-DM: is Abbott’s remaining pharmaceutical business after Abbott separated into two independent companies in January 2013: Abbott and AbbVie. Abbott EPD-DM is active within the EU in therapeutic areas including gastroenterology, women’s and men’s health, cardiology, metabolic disorders, anti-infective/respiratory and Central Nervous System. |
| --- | --- |

2.

The business activities of the undertakings concerned are:

—   Mylan: a global pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals,

Mylan

—   Abbott EPD-DM: is Abbott’s remaining pharmaceutical business after Abbott separated into two independent companies in January 2013: Abbott and AbbVie. Abbott EPD-DM is active within the EU in therapeutic areas including gastroenterology, women’s and men’s health, cardiology, metabolic disorders, anti-infective/respiratory and Central Nervous System.

Abbott EPD-DM

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7379 — Mylan/Abbott EPD-DM, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number M.7379 — Mylan/Abbott EPD-DM, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

---